跳至主要内容
临床试验/NCT01131910
NCT01131910已完成2 期

Efficacy of TBE-vaccine to Patients With Rheumatic Disease Who Are Treated With Methotrexate and/or TNF-alfa Blocking Drugs

Sormland County Council, Sweden8 个研究点 分布在 2 个国家目标入组 68 人开始时间: 2010年5月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
68
试验地点
8
主要终点
Seroconversion rate

研究概览

简要总结

The investigators intend to check whether the efficacy of a TBE-vaccine is substantially deteriorated in patients with rheumatoid arthritis who are treated with drugs which suppress the immune system. The investigators aim to detect a difference of at least 10 % compared to healthy individuals (historical controls) in protection when analysed with serology. If the investigators detect a difference, the investigators will continue to explore whether protection can be achieved by additional doses

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Rheumatoid arthritis treated with methotrexate and/or TNF-alfa blocking drugs
  • Interest to be vaccinated
  • Written consent
  • Age 18 years or more

排除标准

  • Previous TBE-infection
  • Previous Vaccination with TBE
  • Pregnancy
  • Breast feeding
  • Treatment with rituximab the last 9 months
  • Inability to follow study protocol

结局指标

主要结局

Seroconversion rate

时间窗: 1 year

The humoral response to TBE-vaccine

次要结局

未报告次要终点

研究者

发起方
Sormland County Council, Sweden
申办方类型
Other

研究点 (8)

Loading locations...

相似试验